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Abstract 
More than 250 years ago William Hunter stated that when cartilage is destroyed it 
never recovers 1. In the last 20 years, the understanding of the mechanisms that lead to joint 
formation and the knowledge that some of these mechanisms are reactivated in the 
homeostatic responses of cartilage to injury has offered an unprecedented therapeutic 
opportunity to achieve cartilage regeneration. Very large investments in ambitious clinical 
trials is finally revealing that, although we do not have perfect medicines yet, disease 
modification is a feasible possibility for human osteoarthritis. 
Developmental morphogenesis and homeostatic responses to injury 
share basic mechanisms 
During embryonic development, mesenchymal cells deriving from the lateral plate 
mesoderm (LPM), condense within the limb bud to form a cartilage anlage. The 
chondrocytes in the centre (diaphysis) of the skeletal elements undergo hypertrophic 
differentiation, expressing collagen type X, VEGF, MMP13 and alkaline phosphatase. 
Hypertrophic differentiation, in turn, triggers mineralization and ultimately replacement by 
bone 2,3. Endochondral ossification proceeds from the diaphysis towards the epiphysis 
sparing the joint interzones, which separate the future skeletal elements and will give rise to 
the joints. The joint interzones are composed of a distinct population of chondrogenic 
precursors expressing GDF5, WNT9A, WNT16 and other markers. Sox9+ cells from the limb 













mesenchyme are recruited to the joint interzone where they transiently express Gdf5 7. 
Cavitation through the middle of the joint interzone completes the separation of the skeletal 
elements. The first cells recruited to the Gdf5+ interzone lineage contribute largely to the 
epiphyses; cells recruited at later stages contribute to the articular cartilage and finally to the 
other soft tissues of the joints, including menisci, synovial membrane, ligaments and tendons 
3–6. WNT signaling is required and sufficient for joint formation. While the deletion of 
individual genes results in minor phenotypes – for instance, deletion of Wnt9a results in 
synovial chondromatosis 8, possibly because of compensation - complete suppression of 
WNT signalling resulted in joint fusion 9,10. Misexpression of WNT9A was sufficient to induce 
interzone markers including Gdf5, but not the formation of ectopic joints 10. Gdf5-null mice 
lack some distal skeletal elements in the autopod, and also have anomalies in the proximal 
joints: for instance, the knees are missing the menisci and the cruciate ligaments 6,11. The 
more severe phenotype in the distal skeletal elements is possibly due to the proximo-distal 
expression gradient of Gdf5 compared to other BMPs which may partially compensate in the 
proximal joints. Deletion of c-Jun, which is upstream of Wnt9a in the joint interzones, also 
resulted in lack of joint cavitation 12, however, morphologically, joint interzones were still 
present both after WNT blockade and c-Jun deletion 9,12. Therefore, while substantial 
progress has been made in the understanding of joint morphogenesis and maturation, the 
prime mechanisms determining joint specification remain elusive. 
 As opposed to the epiphyseal cartilage, the articular cartilage is stable throughout 
life, resistant to hypertrophic differentiation and endochondral ossification.  Once the 
skeleton is mature, in adult life, the articular cartilage enters a status of extremely low 
turnover 13. However, shortly after injury the articular cartilage deploys an impressively rapid 
homeostatic response that, in many cases, restores integrity and function 14. This repair 
response is triggered by the re-activation of several of those molecules which during 
development mark the joint interzone and are not normally expressed in quiescent uninjured 
adult cartilage 15. These responses contribute to healing 16 and to re-establishing 
homeostasis 17,18. Spontaneous healing is most likely to be successful for small isolated 
lesions in otherwise healthy and young patients. With age, joint instability and other 
comorbidities including obesity, the likelihood of successful repair decreases 14.  
If repair is unsuccessful, or if injury persists, the excessive or prolonged molecular 
responses to injury may become a pathogenic factor leading to ectopic activation of 
hypertrophic differentiation and mineralization within the articular cartilage. This, in turn, 
drives further cartilage loss and development of osteoarthritis 19–21. 
Osteoarthritis is the most common cause of disability for which we have no cure 22. 
Targeting basic mechanisms shared by developmental morphogenesis and injury responses 
has allowed researchers to aim for cartilage regeneration for disease modification (Fig 1). 
One key example of this is ectopic chondrocyte hypertrophy: while hypertrophic 
differentiation is essential for normal development of the appendicular skeleton, adult 
articular chondrocytes should not undergo hypertrophy. When homeostasis is disrupted, a 
series of events requiring the transcription factor HIF-2α induce ectopic hypertrophy within 
the articular cartilage; the articular cartilage becomes mineralized and further cartilage loss 













ensues 19–21 (Fig 2). Indeed, genetic deletion of Hif-2α in adult cartilage protected 
chondrocytes from ectopic hypertrophic differentiation and resulted in decreased cartilage 
degradation in murine models of osteoarthritis 20,21. Additional mechanisms shared between 
developmental morphogenesis and homeostatic responses to injury are shown in Fig 1 and 
summarized in table 1. 
 
Table 1. Processes with roles in both skeletal development and osteoarthritis. 





















Apoptosis Joint cavitation; 
replacement of 
cartilage by bone 

























TGF-β, BMPs 5,40 
 
At this point the main questions were: how can we utilize such mechanisms to 
support cartilage repair? What are the molecules that, in injured adult cartilage, become 
reactivated and regulate these processes? What initiates production of stable cartilage, 
which doesn’t result in bone formation? A transcriptomic analysis of adult articular cartilage, 
24 hours after injury, revealed the re-expression of morphogenetic signals that play 
important roles during joint development but are otherwise inactive in the adult cartilage 
including the WNT, TGF-β/BMP, Hedgehog, and FGF signalling pathways 15,16,41.  
The re-activation of such molecules in the acute-injury phase have long-term 
consequences on the outcome of repair. The focus on early morphogenetic events is a 
complete change of perspective compared to the previous emphasis, in osteoarthritis 
research, which targets late, downstream events such as extracellular matrix production and 
degradation. Two examples are the re-activation of WNT16 and PTHR1/PTHrP in adult 
cartilage after injury. 
 













The case of WNT16  
Wnt16 is one of the earliest markers of the joint interzone 9,10, but is undetectable in 
adult cartilage 15,17. We showed that 1 day after injury, WNT16 became abundantly re-
expressed in cartilage and canonical WNT signalling became activated 15. The re-expression 
of WNT16 after injury was transient, however adult mice lacking Wnt16 developed more 
severe cartilage loss and osteoarthritis 8 weeks following joint destabilization 17. During its 
injury-induced expression, WNT16 supported the maintenance and activity of a Prg4+ stem 
cell population within the superficial layer of the articular cartilage 42,43, while at the same 
time preventing more potent WNT agonists from uncontrollably activating the β-catenin-
dependent pathway, which would lead to ectopic cartilage hypertrophy and ultimately loss of 
cartilage 17. Tong et al. showed that Wnt16 overexpression protected cartilage in a model of 
osteoarthritis 44. Wnt16 delayed cartilage breakdown by activating JNK and the WNT planar 
cell polarity pathway, thereby ultimately upregulating PTHrP expression 44. 
 
PTHrP/PTHR1 signalling 
In the periarticular cartilage of the developing skeleton, activation of parathyroid 
hormone receptor 1 (PTHR1) by parathyroid hormone-related protein (PTHrP) increases 
proliferation and inhibits ectopic hypertrophic differentiation 25,26,29,45. This mechanism allows 
elongation of the bones. PTHR1 is not normally expressed in adult articular cartilage. After 
chronic injury, such as in osteoarthritis, PTHR1 was re-expressed and, when stimulated by 
exogenous recombinant human parathyroid hormone, it protected cartilage from breakdown 
46.  
The pathway towards disease modification and clinical 
application 
Manipulation of the molecules driving the homeostatic responses to cartilage injury 
have led to remarkable results in animal models, with a seemingly endless list of potential 
targets. In practice, however, several factors limit clinical applicability. Some molecules play 
important roles in several tissues and targeting these could possibly lead to undesired 
effects. For instance, this is the case of mTOR, which is a central regulator of metabolism. 
The mTOR inhibitor rapamycin improved the outcome of osteoarthritis in mice 47,48, but it has 
severe side effects on overall health. Accessibility is also a limiting factor. Intracellular 
molecules and transcription factors are often difficult to target in humans (RUNX2 27 or HIF-
2α 20,21).  The route of delivery and pharmacokinetics also present limitations: for instance, 
intra-articular injections may limit systemic toxicity, but they are painful and would not be 
tolerated by patients if required too frequently. 
 
Hereafter we review, using three examples, the path that has led to clinical 
experimentation and, in some cases, successful clinical trials.   













Blockade of WNT signalling 
WNTs are a family of secreted morphogens originally discovered for their role in 
oncogenesis and subsequently well studied for their role in embryonic morphogenesis 49. In 
the absence of WNTs, β-catenin is constitutively degraded. When so-called “canonical”  
WNTs such as WNT1 or WNT3A bind to frizzled (FZD) receptors and to their co-receptors 
LRP5 and LRP6, the molecular complex responsible for β-catenin degradation is disrupted. 
This causes β-catenin to accumulate in the cytoplasm, translocate to the nucleus where it 
binds to TCF/LEF transcription factors and contributes to the activation of target genes 49. 
Other WNTs activate pathways collectively denominated “non-canonical”, mediated by 
different co-receptors including ROR1 and ROR2 50,51.  
Early cell and developmental biology experiments showed that the canonical WNT 
pathway regulates skeletogenesis 24,52–54 and joint morphogenesis 9,10,24. In broad terms, 
these studies suggested that activation of canonical WNT signalling inhibited 
chondrogenesis in progenitor cells and initiated hypertrophic differentiation in mature 
chondrocytes 24.  
Wnt4, Wnt9A and Wnt16 are the earliest markers of joint interzones 9,10. Although 
WNT signalling is essential for joint formation 9,10,55–57, the specific functions of individual 
ligands and receptors are largely redundant. Their function in development and adulthood 
are summarized in table 2. 
 
Table 2. Roles of WNTs in cartilage development and adulthood 
Molecule Development Adult cartilage 
WNT3A Maintains mesenchymal stem cells in an 
immature state in the developing limb bud, in 
chicks induces expression of FGF8 in the 
apical ectodermal ridge, promoting its formation 
58–60  
Dose-dependent activation 




dependent pathways leading 
to dedifferentiation of 
chondrocytes 61.  
WNT4 Expressed at site of future joint formation 10. 
Promotes chondrocyte differentiation and 
hypertrophy 10, regulating the transition from 
pre-hypertrophy to hypertrophy 8, but is also not 
strictly required for normal joint formation 58. 
Synergises with WNT9A in 
preventing ectopic 
chondrogenic differentiation 
of synovial MSCs 8  
WNT5A Expressed in the perichondrium 62 and 
regulates limb outgrowth through the planar cell 
polarity pathway, by activating ROR2 and 
Vangl2 63,64. Inhibits chondrocyte transition from 
Reduces COL2A1 and 
Aggrecan, and induces 
MMP1 and MMP13 
expression in osteoarthritic 
chondrocytes 67. 













a resting state to proliferative. It is required for 
the transition from proliferative to pre-
hypertrophic state, but blocks hypertrophy. 
Knockout and overexpression of WNT5A show 
similar phenotypes in vivo 10,64–66.   
WNT8 Expressed in the perichondrium. Promotes 
chondrocyte hypertrophy and calcification 24. 
 
WNT9A Expressed at site of future joint formation 10. 
Blocks and can reverse chondrocyte 
differentiation 8–10. 
 
Ectopic expression in chick limbs induces 
ectopic joint interzone formation 9,10 - but not 
required for joint formation 8.  
Wnt9A deficient mice 
develop synovial 
chondromatosis 8 
WNT16 Early marker of joint interzone 9. 
 
Prevents chondrocyte hypertrophy 44. 
Buffers activation of β-
catenin pathway by stronger 
canonical WNT ligands. 
Promotes cartilage 
homeostasis by maintaining 





of β-catenin  
Joint fusion and delayed endochondral 
ossification 9,24,55,68. Reduced lubricin and 
COL2A1 expression 4. 
Increased proteoglycan 
content and reduction in 
endochondral ossification in-
vitro 24.  
Increased chondrocyte 
apoptosis and articular 






Blocks and can reverse chondrocyte 
differentiation 4,8–10,71. 
Ectopic expression of constitutively active β-
catenin in chick limbs induced ectopic joint 
interzone formation 9,10 . 
Promotes chondrocyte 
differentiation, hypertrophy 
and cartilage calcification 
9,24,37,55–57,62. ; Catabolism of 
cartilage extracellular matrix 
and chondrocyte apoptosis 
54,57,72.  













Worse outcomes in rodent  
OA models with cartilage 
loss and osteophyte 
formation 54,73 . 
 
In adult cartilage, both inhibition 70 and forced activation of β-catenin signalling 73 led 
to cartilage destruction in mice. This is because a population of cartilage-specific 
chondroprogenitors expressing Prg4 42 are dependent on β-catenin signalling 43 whereas 
excessive WNT activation inhibits chondrogenesis and drives hypertrophy in already 
differentiated chondrocytes 9,24,37,56. 
Consequently, a “Goldilocks” theory took hold whereby WNT activation needs to be 
above a certain level in order to maintain progenitor cell populations, but below levels which 
drive hypertrophic differentiation in mature chondrocytes. Further complexity was added by 
the understanding that while a short burst of WNT activation supports articular cartilage 
formation and homeostasis 17,57, excessively prolonged activation resulted in cartilage 
breakdown. Interestingly, WNT16 is both required and sufficient for cartilage homeostasis 
following cartilage injury 17,44, and it is a partial activator of the canonical WNT pathway, 
maintaining “homeostatic levels” and preventing excessive activation from other more potent 
ligands 17,44. 
The relevance of these findings to human osteoarthritis was confirmed by the 
association of allelic variants of WNT inhibitory molecules such as FRZB 74 and DOT1L 75 
with osteoarthritis. These data were replicated in animal models 28,54. 
These exciting data triggered the search for WNT inhibitors which could be used to 
treat osteoarthritis. Given the high level of redundancy of WNT ligands and receptors, it was 
unlikely that WNT inhibition outside or at the level of the cell membrane would be successful. 
Inhibition of WNT signalling through upregulating FRZB, by Verapamil 76, or with a small 
molecule XAV-939 77 led to improved outcomes of osteoarthritis in animal models.  
Deshmukh et al. identified a small compound (SM04690, now commercialized by 
SAMUMED as Lorecivivint) which, by inhibiting the intracellular kinases CLK2 and DYRK1A, 
inhibited WNT signalling downstream of β-catenin 78,79. SM04690 proved to have a 
remarkable pharmacokinetic profile: after intra-articular administration in rats it could not be 
detected in plasma, it was detected just above therapeutic levels in bone, but it accumulated 
in cartilage for at least 180 days 79. A single intra-articular administration of SM04690 
improved structural outcomes in an instability-induced osteoarthritis model and improved 
structural outcomes, pain and weight-bearing in the monosodium iodoacetate model in rats 
79. In a phase I clinical trial, a single intra-articular injection of SM04690 proved to be safe 
after one year follow-up in patients with osteoarthritis (Kellgren-Lawrence score 2-3). 
Although the study was not designed for, and was vastly underpowered to test efficacy (61 
patients in total followed up for one year), pain parameters were improved at all doses and 
joint space width was improved in the intermediate dose 80. A phase II study, although it did 
not meet its primary endpoint, confirmed pain relief and some evidence of improvement of 
joint space width in patients with unilateral osteoarthritis at an intermediate dose 81. 













Interestingly, and in keeping with the notion of a “Goldilocks zone” of WNT activation, the 
intermediate dose yielded the best results. Whether the long-term efficacy of this compound 
after a single injection is due to its long-term accumulation in cartilage 79 or that perhaps the 
initial delivery is sufficient to trigger a self-maintaining homeostatic cascade is unknown. 
Although these results are promising, phase III studies are required to demonstrate efficacy. 
One important contribution of this paper was the improvement of the clinical trial 
technology in osteoarthritis. In particular, the finding that selecting patients with unilateral 
symptoms and without widespread pain allows a higher level of sensitivity, especially in 
terms of pain, will greatly facilitate future studies with this or other compounds. 
TGF-β and bone morphogenetic proteins 
In 1965 Urist and Daly published the seminal paper “Bone: formation by 
autoinduction” in which they described that ectopic implantation of demineralised bone 
matrix triggered ectopic endochondral bone formation, ultimately leading to the formation of 
an ossicle made by cells originating from the host organism 82. They also correctly 
hypothesised that some substance contained in the acellular bone matrix would be 
responsible for initiating the morphogenetic events leading to bone formation. In the years 
that followed, several groups went on to identify a family of molecules, named Bone 
Morphogenetic Proteins (BMPs), which, when implanted in an appropriate matrix, resulted in 
ectopic cartilage and bone formation 83–85. It became apparent that, far from being specific 
cartilage/bone growth factors, BMPs had a broad array of functions in different cells, stages 
of development and adult life. Regulation of the BMP pathway is essential for gastrulation, 
the formation of mesenchyme in early development, establishing the dorso/ventral patterning 
and the morphogenesis of virtually all organs 86,87.  
In spite of relatively stereotypical, shared signalling mechanisms and similar in vitro 
effects on skeletal cells, the expression pattern and the biological activity of different BMPs 
in vivo varies enormously. This is exemplified by the elegant studies in the chick model in the 
Hurle laboratory in the mid 1990s 88. Macias et al. showed that BMP7 is expressed in the 
diaphyseal perichondrium, skipping the joint interzone, and when delivered next to a joint 
interzone, it inhibited joint formation. Conversely, BMP2 was expressed in the joint interzone 
and its ectopic delivery resulted in ectopic joint-like structures 88.  
Because of the capacity of BMPs to induce cartilage and bone formation, several 
products were generated and tested for the repair of critical size defects, non-unions and 
spinal fusions 89–92, however, over forty years after the discovery of BMPs, the results of 
clinical testing in osteoarthritis and chondral defects are underwhelming 93. This could be 
due to several factors, but the stability of these molecules in inflammatory sites, their 
pleomorphic function in different settings and different cells, and especially their propensity 
to induce ectopic cartilage and bone represent serious issues 92,94. Overexpression of BMP2 
in adult joints resulted in ectopic cartilage and bone formation within the joint soft tissues 95 
and additional cartilage degradation through upregulation of matrix metalloproteinases 96. 













To circumvent this problem, investigators have tested the use of transforming growth 
factor (TGF)-β. TGF-β is a potent inducer of chondrocyte differentiation in a variety of stem 
cells, promoting SOX9 expression, extracellular matrix production 97–99.   
In humans, a genetic association of alleles of TGF-β and downstream molecules with 
osteoarthritis was identified 100. In keeping with this, transgenic expression of a dominant 
negative Tgf-β receptor 2 (Tgf-βr2) led to formation of hypertrophic cartilage and an 
osteoarthritis-like phenotype 101. However, in vivo, TGF-β overexpression exacerbated 
osteoarthritis, whereas its inhibition was beneficial in murine models 102. This was true when 
using the TGF-β inhibitor halofuginone 103, an antibody against TGF-β1, systemic delivery of 
a TGF-βR1 inhibitor or by knocking out Tgf-βr2 in nestin-positive MSCs 102. 
The discrepancy between the requirement of TGF-β signalling in joint homeostasis 
and its negative effect when overexpressed in osteoarthritis remains enigmatic. One 
explanation was offered by Blaney-Davidson et al. who demonstrated that upregulation of 
ALK1 receptor switches TGF-β signalling from SMAD2/3 which inhibits chondrocyte 
hypertrophy to SMAD1/5/8 downstream, which induces chondrocyte hypertrophy 104,105.  
The disappointing results of the use of TGF-β and BMPs in cartilage repair can be 
attributed to the fact that although BMP and TGF-β signalling are essential for cartilage 
morphogenesis and homeostasis, their function is tightly regulated both spatially and 
temporally, and inappropriate or excessive activation are detrimental.  
FGF18 
Fibroblast growth factor (FGF) signalling was one of the first pathways discovered to 
be activated by cartilage injury. It contributes to repair responses through release of FGF2 
from the injured articular cartilage 106,107. However, FGF2 activates both FGF receptor-1 
(FGFR1) and FGFR3, the former associated with prevalently catabolic effects on articular 
cartilage and the latter promoting anabolic events 108,109.  
Mutations of FGF receptors result in a variety of skeletal defects 110. With few 
exceptions, mutations of FGFR1 and FGFR2 result in defects of skeletal elements that form 
through intramembranous bone formation (craniosynostoses and similar syndromes); 
whereas mutations in FGFR3 result in dwarfisms caused by defects of the bones that form 
through endochondral bone formation. For all these reasons, FGFR3 signalling was 
considered a suitable target for articular cartilage homeostasis. Dominant activating 
mutations in FGFR3 resulted in hypochondroplasia, achondroplasia 111 and thanatophoric 
dysplasia 112. Recessive loss-of-function mutations of FGFR3 resulted in camptodactyly, tall 
stature, scoliosis, and hearing loss syndrome (CATSHL syndrome) 113. Mice lacking Fgfr3 
114,115 had features resembling CATSHL syndrome, whereas mice with activating mutations 
of Fgfr3 had features similar to achondroplasia 116. The skeletal defects were due to a delay 
in chondrocyte hypertrophy and endochondral bone formation. Given the pathogenic role of 
ectopic chondrocyte hypertrophy in the adult articular cartilage, this property of FGFR3 
signalling supported its activation to prevent osteoarthritis progression. 













In addition to halting chondrocyte hypertrophy and endochondral bone formation, 
FGFR3 is essential for the differentiation of mesenchymal cells into chondrocytes, as limb 
bud mesenchymal cells from Fgfr3 knockout mice failed to undergo chondrogenesis in 3D 
culture and to proliferate in monolayer 117. Finally, the expression of FGFR3 is associated 
with the capacity of adult articular chondrocytes to form stable articular-like cartilage in vivo 
108 and to repair cartilage defects in goats 118 and humans 119,120.  
Activating FGF receptors only in cartilage is difficult because FGFs are ubiquitous, 
pleiotropic and several FGF ligands can signal through multiple FGFRs. Fortunately, FGFR3 
is mostly expressed in cartilage, its mutations result almost exclusively in skeletal 
phenotypes.  FGF18, a selective ligand for FGFR3, promoted chondrocyte proliferation and 
differentiation 121 117. Alleles of FGF18 were genetically associated with osteoarthritis in 
humans 100. Therefore, recombinant FGF18 was tested as a therapeutic for osteoarthritis. 
Moore et al. showed that intra-articular injections of recombinant FGF18 induced 
chondrocyte proliferation and cartilage repair when delivered in a therapeutic regime in rats 
subjected to a severe model of instability-induced osteoarthritis 122. 
Two large clinical trials provided evidence that treatment with intra-articular 
recombinant FGF18 (developed by Merck and Nordic Bioscience as Sprifermin) resulted in 
some degree of improvement of cartilage integrity in osteoarthritis 123,124. However, 
symptomatic improvement which was suggested in the first trial (phase I) 124 was not 
replicated in the subsequent larger trial (phase II) 123. Clearly, pain is a fundamental outcome 
for patients. We do not know whether the failure to detect pain improvement with FGF18 was 
due to trial design, for instance by not excluding patients with widespread chronic pain, or 
whether FGF18 treatment does not result in pain relief. Published pre-clinical data in animal 
models did not include pain measurements 122. A corollary is that, in the absence of pain 
relief, it is difficult to judge the clinical relevance of the small degree of improvement in joint 
space narrowing reported by the authors. 
Taken together, data on inhibition of WNT signalling and using FGF18 suggest that 
targeting homeostatic pathways has led us to turn the corner in developing pharmacological 
approaches for treating osteoarthritis. It is likely that improvements in clinical trial design and 
patient stratification will be key to measure efficacy. 
From cell-based therapeutics to stem cell niches 
In the mid-1990s Brittberg et al. successfully repaired full thickness cartilage defects 
by implanting autologous chondrocytes that had been briefly expanded in vitro 125. Since 
then, autologous chondrocyte implantation (ACI) has been tested in multiple clinical trials 
and has resulted in good and persistent clinical and structural benefits 126,127. Unfortunately, 
due to the autologous nature of the cells, these technologies are extremely laborious, costly, 
are not easily upscalable and therefore have not reached routine clinical application.  
Transplantation of mesenchymal stem cells (MSCs) of various origins into cartilage 
defects have also shown some degree of efficacy, although the clinical trials so far have 
been much smaller than those with chondrocytes 128. Stem cells are clonogenic cells that 













have two remarkable features: the ability to differentiate into multiple lineages (multipotency) 
and the ability to simultaneously replenish the stem cell pool (self-renewal) 129. Bone marrow 
mesenchymal cells, the first adult MSCs identified, were originally discovered as plastic 
adherent, non haematopoietic clonogenic cells that can differentiate into multiple skeletal 
lineages including adipogenic, osteogenic and chondrogenic 130–132.  
The subsequent discovery that multiple stem cell populations persist within adult 
skeletal tissues 37,38,97,98,118,131 opened up the possibility of harnessing the regenerative 
machinery of the adult joint by recruiting local resident stem cells to the site of damage. 
Stem cells originating from different tissues - such as the synovial membrane 97, the 
periosteum 98 , the bone marrow 133 and the cartilage itself 42,118,134 have distinct “default” 
differentiation pathways 135–137. The development of lineage tracking technologies enabled a 
much more sophisticated understanding of the nature and function of different progenitor 
lineages in development and in post-natal repair. 
The pressing questions in order to pursue this opportunity are: why are there so 
many different stem cell types? Do they differ in their repair capacity? What are the 
molecules that govern their niches?  
Progenitor lineages within the developing limb bud persist and contribute 
to healing in the adult skeleton 
The development of the appendicular skeletal elements requires the proliferation and 
migration of mesenchymal cells from the LPM to form the limb bud 138–141. The MSCs at the 
periphery of the limb bud are maintained in an undifferentiated state by molecular signals 
(specifically FGF8 and WNT3A) which are released from the apical ectodermal ridge (AER) 
and surrounding ectoderm respectively 58,142–146. However, in the centre of the limb bud, 
away from the control of these signals, MSCs aggregate into the mesenchymal 
condensations to form the skeletal anlage. From the early stages of limb development, the 
anlage appears to be composed of distinct cell populations which give rise to specific cell 
lineages and sub-lineages, and ultimately to different skeletal structures (Fig 3) 2,60,140,147. 
PRX1+ progenitors 
Paired Mesoderm Homeobox 1 (PRX1) is one of the first progenitor cell markers that 
appears in the limb bud. Prx1 is expressed as early as 9.5 days post coitum (dpc), stemming 
directly from the LPM, and by 10dpc it can be detected in almost all the skeletal 
mesenchyme in the limb, including the condensing mesenchyme, chondrocytes, periosteum 
and tendons 148–150. By 15dpc however, the expression of Prx1 becomes restricted to the 
periosteum and tendons 150. The Prx1-expressing periosteal cells are maintained after birth 
and retain their capacity to differentiate into chondrocytes in vitro, suggesting that that these 
periosteum-Prx1+ cells are both chondro- and osteo-progenitor cells 91,150,151. 













The generation of Prx1-cre mice and their crossing to suitable reporters have 
demonstrated that Prx1-lineage progenitor cells give rise to all the cell sub-lineages that 
contribute to the formation of the bony elements, the articular cartilage, tendons and 
ligaments 91,150. Prx1+ cells also persist as MSCs postnatally within the periosteum where 
they contribute to callus formation after bone fracture 152.  
The Prx1 lineage arises from a still earlier mesenchymal lineage expressing platelet-
derived growth factor receptor α (Pdgfrα) 153–155 which appear as early as 6.5 dpc. 
Interestingly, Pdgfrα is also a marker of progenitor cells which persist within the adult 
synovial membrane, and that contribute to cartilage repair 38. 
Within the Prx1+ population, two distinct MSC populations emerge. Osterix+ cells 
give rise to calcified tissues including bone 156,157 and the calcified layer of the articular 
cartilage 42; and Gdf5+ cells which give rise to the articular cartilage and other soft tissues of 
the joints including ligaments and tendons 4–6. 
Osterix+ progenitors 
During embryonic development Osterix (Osx) is expressed by both the epiphyseal 
chondrocytes where it promotes hypertrophic differentiation 157 and by an MSC population 
residing around the vessels of the perichondrium 156. Subsequently, the Osx+ periosteal 
precursors enter the hypertrophic cartilage accompanying the ingrowing vessels and give 
rise to osteoblasts to form the bone replacing the hypertrophic cartilage 156. 
Multiple separate cell lineages were detected within developing epiphyses including 
Gremlin+ 158, Nestin+ 159 and LeptinR+ 156,160,161 progenitor cells. Whereas their identity, 
marker profile, and differentiation potential has been well-studied in embryonic development, 
their persistence as distinct progenitor populations in adulthood and particularly their 
contribution to tissue repair is unclear. For instance, Nestin+ cells persist in the perivascular 
spaces of the periosteum 162 and in the adult synovial cells 38, however, in the absence of 
proper lineage tracking, their respective contribution to fracture and cartilage repair remains 
unconfirmed 38,162. 
Scx+SOX9+ progenitors 
Progenitor cells which contribute to the formation of tendons and their attachment to 
bones (entheses) express Scleraxis (Scx) and Sox9 163–166. Scx was required for the 
formation of tendon-to-bone attachment sites 167. TGF-β and BMP4 signalling were essential 
for the specification and differentiation of Scx+Sox9+ progenitors, respectively 167. Further 
analysis was able to dissect another distinct subset of progenitors from this pool, those 
which are Scx+Sox9-; both Scx+Sox9+ and Scx+Sox9- progenitors can differentiate into 
tenocytes, however, those closest to the cartilaginous primordium are mostly derived from 













the Sox9+ population 166. The Scx+Sox9+ lineage persist in the adult enthesis and 
periosteum 164 and contribute to tendon and fracture healing 164,168–170. 
Joint progenitors 
The cells that form the adult articular cartilage derive from two main lineages: the 
superficial and intermediate zone are contributed from progenitor cells deriving from Prg4+ 
progenitors 4,42,43, whereas the deep layer, which is calcified, is contributed and renewed by 
Osx+ progenitors 42 and therefore can be considered a remnant of the epiphyseal growth 
plate.  
GDF5+ progenitors 
During embryonic development, Gdf5/Cdmp1 is expressed within the portion of the 
cartilage anlage that forms the embryonic skeleton and is destined to give rise to the 
permanent articular cartilage. Lineage tracking experiments showed that all soft tissues 
(such as the articular cartilage, meniscus, synovial lining, and joint capsule) within the joint 
are composed of cells that, within the interzone, derive from the Gdf5+ progenitors 4–6. Until 
recently, Gdf5 lineage cells were thought to be determined early during embryonic 
development and represented a stable population. Challenging this hypothesis, Shwartz et 
al. elegantly demonstrated that there is a constant inflow of Gdf5-lineage cells recruited to 
the joint interzone throughout development from the surrounding Sox9+ mesenchyme and, 
depending on the time when such recruitment occurs, they contribute to different joint 
structures: the first cells to be recruited contribute to the epiphyses, then to the articular 
cartilage and the last ones to menisci and cruciate ligaments 6. In addition, these studies 
demonstrated that far from being a “stable marker”, Gdf5 expression in the interzone cells is 
transient. 
Gdf5-lineage cells have recently been shown to persist in the adult joint in the 
perivascular spaces of the synovial membrane and to contribute to the repair of cartilage 
injuries 37,38.  
LGR5+ progenitors 
A subpopulation of Gdf5 lineage progenitors acquire the expression of Lgr5 and 
Col22a1 and give rise specifically to cruciate ligaments, synovial membrane, and articular 
chondrocytes 171. LGR5 is a receptor that amplifies the effect of β-catenin dependent WNT 
signalling through binding R-spondins 172, a signalling pathway that the progenitor cells of 
the superficial cartilage layer are strictly dependent on 43. Implantation of embryonic Lgr5+ 
cells into an adult murine cartilage defect resulted in cartilage repair 171, however it is not 
known if Lgr5+ cells persist in the adult joint and, if so, whether they contribute to cartilage 
healing. 













Interestingly, however, Lgr5 expression is detected in the Gdf5-lineage population, 
prior to the expression of Prg4 171, an additional chondro-progenitor which largely resides in 
the surface of the articular cartilage. 
Prg4+ progenitors 
Prg4 (the gene encoding lubricin) is expressed in the mouse joint interzones starting 
from 15.5dpc 4. With time, the expression of Prg4 increases and Gdf5 decreases 4. PRG4 
expression persists throughout adult life at the surface of the articular cartilage and within 
the synovium but is not detectable in the growth plate cartilage 173. Prg4+ progenitor cells 
within the superficial layer of the articular cartilage contribute to the turnover of chondrocytes 
of the non-calcified cartilage layers throughout life 42 but it is likely that it is the synovium-
residing Prg4+ progenitors that contribute to cartilage healing after injury 37. By combining 
nucleoside labeling, Prg4 lineage tracking and Confetti mice, Decker et al. showed that 
Prg4+ progenitors proliferated within the synovial membrane, migrated and contributed to 
repair of cartilage defects. Prg4+ cells residing within the cartilage adjacent to the defect 
sites did not proliferate or contribute to repair 37. Interestingly, Seol et al showed that the 
transcription factor Hmgb-1 released by dying chondrocytes functions as a chemoattractant 
for Prg4+ progenitor cells, thereby possibly supplying a mechanistic explanation of their 
recruitment to the site of damage 174. 
The overlap between the Gdf5+ and the Prg4+ progenitor populations in mature 
cartilage is not definitively established, given the absence of dual lineage tracking, however, 
experiments from the Pacifici laboratory suggest that Prg4 positivity is a feature of the 
differentiating Gdf5+ cells 4. 
  
Summary 
The identification of different stem cell lineages with unique roles during 
development, homeostasis or the repair of musculoskeletal tissues is a major step forward in 
regenerative medicine. The understanding of the molecular control of stem cell niches, their 
maintenance, proliferation, migration and differentiation is revealing molecular tools to trigger 
repair by mobilizing progenitor cells. This may enable timely morphogenesis of the repair 
tissues without the need for expensive and laborious cell manipulations outside of the body. 
These approaches will generate upscalable, affordable production of effective and safe off-
the-shelf therapeutics for the treatment of cartilage defects or osteoarthritis.  
 














As described in this review, several molecular targets are now available to treat 
cartilage degeneration. Clinical success will depend on our ability to understand the 
hierarchy of the homeostatic signals and the reason for repair failure in individual patients. 
Molecular hierarchy. Interactions between the biological pathways and stem cells 
that contribute to skeletal homeostasis makes it hard to unpick the role of individual 
molecules, and the changing landscape of ligand/receptor/signalling molecule expression as 
cartilage degenerates must be carefully considered. The identification of key players that can 
initiate the repair cascade, from the recruitment of the stem cells from their niches to 
establishing morphogenesis of the repair tissues, without affecting the surrounding healthy 
tissues will be key to achieve affordable, effective and safe therapeutic interventions. 
Patient stratification. Failure of repair/homeostasis in different patients may depend 
on different mechanisms. For instance some patients may fail to repair because of poor stem 
cell recruitment, while others will progress because of poor tissue patterning or failure of 
differentiation. The selection of the right treatment for the right patient can be achieved with 
the identification of downstream targets of the homeostatic signals which can be used to 
identify the failure mechanism and at the same time as surrogate efficacy markers.  
Pharmacokinetics. The timing, duration, delivery method and dosing of the 
interventions within the appropriate tissues will be critical. For instance, a brief, well-dosed 
activation of WNT signalling is beneficial for cartilage health under certain conditions 57, but 
persistent WNT activation is detrimental and even a burst of activation in patients with 
already established osteoarthritis, where WNT signalling is already over-activated, may be 
detrimental. Understanding the pathological processes in individual patients, combined to 
the availability of controlled delivery systems will be key to success.  
 
The understanding of the developmental mechanisms of joint morphogenesis has 
enabled the identification of individual targets and, we predict, will continue to be crucial to 
address some of these key issues. 
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Figure 1. Embryonic morphogenesis and skeletal repair in adulthood share basic processes. 
Proliferation, hypertrophy, apoptosis, stem cell recruitment and morphogenesis are processes which are 
initiated during development to create the joint. These processes are re-activated in injured joint tissues. 
The spatial and temporal regulation of these processes determines the outcome of the injury response, 
either successful regeneration or breakdown. 
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Figure 2. Chondrocyte hypertrophy is required for endochondral bone formation during development but is a 
pathogenic event in the adult osteoarthritic joint. 
During development, epiphyseal chondrocytes undergo hypertrophy and ultimately endochondral bone 
formation. In a healthy adult joint, chondrocytes remain at the joint surface and reside in the permanent 
articular cartilage. Throughout the progression of osteoarthritis, however, these articular chondrocytes begin 
to undergo ‘ectopic hypertrophy’, resulting in the mineralisation and ultimately, breakdown of the articular 
cartilage. 
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Figure 3. Musculoskeletal stem cell lineage tree. 
Condensed mesenchymal stem cells expressing PDGFRα differentiate to express PRX1 in the early limb bud. 
Subsequent differentiation of the PRX1 expressing stem cells recruits them to GDF5, Osterix or the Scleraxis 
lineage, which are responsible for the development of the tissues in the joint, bone and tendons 
respectively. 
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